Category: Lutetium

Clinical preliminary finds solid guarantee for new treatment that objectives radiation straightforwardly to prostate disease

177Lu-PSMA-617 is an individual from another class of medications that demonstration like atomic warheads connected to tumor-homing rockets, conveying radiation straightforwardly to tumor cells to wreck them. These focused on radiation medicines comprise of a radioactive isotope joined to a particle that explicitly targets tumor cells. For this situation, the radioactive isotope is 177-lutetium (177Lu),…
Read more

Lutetium-177 radioisotope focused on treatment for treatment of malignancy and different maladies

By their tendency, radioactive isotopes are unsteady and can change to progressively stable structures by radioactive rot and emanation of various kinds of radiation. This discharged radiation is valuable for malignant growth treatment which incorporates position of “fixed” radioactive sources physically near the illness site (brachytherapy), or by centering the radiation transmitted by an outer…
Read more

Early Treatment of Advanced Prostate Cancer with PSMA-Targeted Radioligand Therapy Prolongs Life

PHILADELPHIA (Embargoed until 12 p.m. EDT, Tuesday, June 26, 2018) – Research exhibited at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) shows out of the blue the advantage of giving prior lutetium-177 (177Lu) prostate-explicit layer antigen (PSMA) radioligand treatment to patients with metastatic prostate disease. As of recently,…
Read more